Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Depreciation and Depletion (2021 - 2024)

Opus Genetics (IRD) has disclosed Depreciation and Depletion for 7 consecutive years, with $3000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Depreciation and Depletion rose 200.0% to $3000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $6000.0, a 50.0% increase, with the full-year FY2024 number at $10000.0, up 66.67% from a year prior.
  • Depreciation and Depletion was $3000.0 for Q4 2023 at Opus Genetics, up from $1000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $3000.0 in Q4 2023 to a low of $1000.0 in Q1 2021.
  • A 3-year average of $1181.8 and a median of $1000.0 in 2021 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: changed 0.0% in 2022, then skyrocketed 200.0% in 2023.
  • Opus Genetics' Depreciation and Depletion stood at $1000.0 in 2021, then changed by 0.0% to $1000.0 in 2022, then surged by 200.0% to $3000.0 in 2023.
  • Per Business Quant, the three most recent readings for IRD's Depreciation and Depletion are $3000.0 (Q4 2023), $1000.0 (Q3 2023), and $1000.0 (Q2 2023).